275 related articles for article (PubMed ID: 21805352)
1. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
2. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Weiss J; Becker JP; Haefeli WE
Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
[TBL] [Abstract][Full Text] [Related]
4. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
Weiss J; Sauer A; Herzog M; Böger RH; Haefeli WE; Benndorf RA
Pharmacology; 2009; 84(5):264-70. PubMed ID: 19776663
[TBL] [Abstract][Full Text] [Related]
5. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
6. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
9. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
Kowalski P; Surowiak P; Lage H
Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
12. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
[TBL] [Abstract][Full Text] [Related]
14. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
15. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
17. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
18. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
19. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
Zembruski NC; Büchel G; Jödicke L; Herzog M; Haefeli WE; Weiss J
J Antimicrob Chemother; 2011 Apr; 66(4):802-12. PubMed ID: 21393174
[TBL] [Abstract][Full Text] [Related]
20. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]